Loading
A phase 2/3 trial of Cytarabine, Daunorubicin, Venetoclax and Azacitidine in acute myeloid leukaemia, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia is a phase 2/3 interventional study registered as NCT07255872 by Sichuan Baili Pharmaceutical Co., Ltd., with 216 participants planned, started 2026-04-02 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M11D1, Cytarabine, Daunorubicin, Venetoclax and Azacitidine.
Shares Daunorubicin, BCL-2 inhibitors, Cytarabine, Azacitidine and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares Daunorubicin, Cytarabine, Azacitidine, Venetoclax and the tag pipeline.